Sign up for free insights newsletter
Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

VRTXMX

Need professional-grade analysis? Visit stockanalysis.com

MX$8,177.00
+1.61%
End of day
Market Cap

$2.28T

P/E Ratio

32.36

Employees

6,400

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-0.172.34-0.720.44
Calmar-0.293.37-0.570.81
Sharpe-0.121.40-0.590.19
Omega1.001.480.851.10
Martin-0.477.71-0.902.08
Ulcer6.744.7720.9412.00

Vertex Pharmaceuticals Inc (VRTX) Price Performance

Vertex Pharmaceuticals Inc (VRTX) trades on MX in MXN. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at MXN8177.00, up 1.61% from the previous close.

Over the past year, VRTX has traded between a low of MXN6850.00 and a high of MXN10235.83. The stock has lost 19.1% over this period. It is currently 20.1% below its 52-week high.

Vertex Pharmaceuticals Inc has a market capitalization of $2.28T, with a price-to-earnings ratio of 32.36.

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Company Info

Exchange
MX
Currency
MXN
Country
Mexico

Financial Metrics

Revenue (TTM)
$12.00B
EBITDA
$4.87B
Profit Margin
32.94%
EPS (TTM)
269.48
Book Value
1294.38

Technical Indicators

52 Week High
MX$10,235.83
52 Week Low
MX$6,800.00
50 Day MA
MX$8,115.52
200 Day MA
MX$7,989.34
Beta
0.32

Valuation

Trailing P/E
32.36
Forward P/E
25.84
Price/Sales
190.33
Price/Book
6.70
Enterprise Value
$2.16T